Luminex Corp. (LMNX) Sees Large Volume Increase
Shares of Luminex Corp. (NASDAQ:LMNX) saw unusually-strong trading volume on Thursday . Approximately 211,991 shares traded hands during trading, a decline of 4% from the previous session’s volume of 220,319 shares.The stock last traded at $21.08 and had previously closed at $20.92.
Several analysts recently issued reports on LMNX shares. Zacks Investment Research lowered shares of Luminex Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, April 14th. Leerink Swann reiterated a “hold” rating and issued a $22.00 price target on shares of Luminex Corp. in a research report on Tuesday, May 3rd. Finally, Piper Jaffray Cos. reiterated a “hold” rating and issued a $20.00 price target (up from $19.00) on shares of Luminex Corp. in a research report on Tuesday, May 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Luminex Corp. presently has an average rating of “Hold” and a consensus price target of $20.83.
The company has a 50-day moving average of $20.19 and a 200-day moving average of $19.71. The company has a market cap of $918.81 million and a PE ratio of 23.82.
Luminex Corp. (NASDAQ:LMNX) last released its quarterly earnings results on Monday, May 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.15. The company earned $63 million during the quarter, compared to analyst estimates of $60.98 million. During the same period in the prior year, the business posted $0.23 EPS. Luminex Corp.’s revenue was up 9.2% compared to the same quarter last year. On average, analysts expect that Luminex Corp. will post $0.67 EPS for the current fiscal year.
Other large investors recently added to or reduced their stakes in the company. EQIS Capital Management boosted its stake in Luminex Corp. by 883.5% in the fourth quarter. EQIS Capital Management now owns 46,942 shares of the company’s stock worth $1,004,000 after buying an additional 42,169 shares in the last quarter. Russell Frank Co boosted its stake in Luminex Corp. by 47.1% in the fourth quarter. Russell Frank Co now owns 238,775 shares of the company’s stock worth $5,167,000 after buying an additional 76,444 shares in the last quarter. DIAM Co. Ltd. boosted its stake in Luminex Corp. by 32.2% in the fourth quarter. DIAM Co. Ltd. now owns 73,009 shares of the company’s stock worth $1,562,000 after buying an additional 17,785 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Luminex Corp. by 259.4% in the fourth quarter. Nationwide Fund Advisors now owns 105,495 shares of the company’s stock worth $2,257,000 after buying an additional 76,140 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Luminex Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 79,760 shares of the company’s stock worth $1,706,000 after buying an additional 1,282 shares in the last quarter.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.